NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Shares of both ITUS Corporation and Nabriva Therapeutics skyrocketed on Monday and experienced phenomenal trading volume compared to usual. A U.S. patent to ITUS' CEO and VP of Engineering for their cancer detection technology sent shares of the stock higher. Nabriva soared over 100% alone in pre-market trading yesterday after announcing that it had met its primary endpoint in a late-stage trial for lefamulin, its pneumonia treatment.

RDI Initiates Coverage on:

ITUS Corporation
https://rdinvesting.com/news/?ticker=ITUS

Nabriva Therapeutics plc
https://rdinvesting.com/news/?ticker=NBRV

ITUS' shares closed up 85.51% on nearly 23 million shares traded on Monday. Trading volume yesterday was explosive for the stock compared to its average of just around 230,000 shares. The big gains came after the company announced that the United States Patent and Trademark Office ("USPTO") had issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and John Roop, VP of Engineering, of the company and its early cancer detection technology. Dr. Kumar remarked, "This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number. We currently have one other key patent application pending at the USPTO and expect to file for additional patent protection as our research and development continues."

Access RDI's ITUS Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ITUS

Nabriva Therapeutics exploded in Monday trading, closing the day up 29.30%. The stock hit a new high of $14.10 during intra-day trading and traded nearly 17.5 million shares compared to an average of just around 80,000 shares. The stock soared as much as over 100% in pre-market trading yesterday after announcing positive late-stage trial results from lefamulin, the company's pneumonia treatment. The company met its primary endpoint and even hit primary endpoints for the European Medicines Agency. CEO Dr. Colin Broom commented, "These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen." The company is finishing up the second phase 3 trial of lefamulin with topline data expected by spring of 2018.

Access RDI's Nabriva Therapeutics plc Research Report at:
https://rdinvesting.com/news/?ticker=NBRV

Our Actionable Research on ITUS Corporation (NASDAQ: ITUS) and Nabriva Therapeutics plc (NASDAQ: NBRV) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com